Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
39.6M
-
Shares change
-
+1.45M
-
Total reported value, excl. options
-
$2.63B
-
Value change
-
+$96.2M
-
Put/Call ratio
-
1.37
-
Number of buys
-
55
-
Number of sells
-
-36
-
Price
-
$66.52
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q2 2018
110 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q2 2018.
Ascendis Pharma A/S - ADR (ASND) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.6M shares
of 55.6M outstanding shares and own 71.21% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (4.41M shares), RA CAPITAL MANAGEMENT, LLC (4.24M shares), FMR LLC (3.34M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.1M shares), BAKER BROS. ADVISORS LP (2.84M shares), Sofinnova Ventures Inc (2.48M shares), Vivo Capital, LLC (2.17M shares), venBio Select Advisor LLC (2.06M shares), EcoR1 Capital, LLC (1.46M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.46M shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.